SE1102739T5 - - Google Patents

Info

Publication number
SE1102739T5
SE1102739T5 SE99936913T SE99936913T SE1102739T5 SE 1102739 T5 SE1102739 T5 SE 1102739T5 SE 99936913 T SE99936913 T SE 99936913T SE 99936913 T SE99936913 T SE 99936913T SE 1102739 T5 SE1102739 T5 SE 1102739T5
Authority
SE
Sweden
Prior art keywords
carbons
halogen
ester
hydrogen
carboxylic acid
Prior art date
Application number
SE99936913T
Other languages
English (en)
Other versions
SE1102739T3 (cg-RX-API-DMAC10.html
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed filed Critical
Publication of SE1102739T3 publication Critical patent/SE1102739T3/xx
Publication of SE1102739T5 publication Critical patent/SE1102739T5/xx

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C69/00—Esters of carboxylic acids; Esters of carbonic or haloformic acids
    • C07C69/76—Esters of carboxylic acids having a carboxyl group bound to a carbon atom of a six-membered aromatic ring
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D295/00—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms
    • C07D295/16—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms acylated on ring nitrogen atoms
    • C07D295/18—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms acylated on ring nitrogen atoms by radicals derived from carboxylic acids, or sulfur or nitrogen analogues thereof
    • C07D295/182—Radicals derived from carboxylic acids
    • C07D295/192—Radicals derived from carboxylic acids from aromatic carboxylic acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A61P27/06—Antiglaucoma agents or miotics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/14—Drugs for disorders of the endocrine system of the thyroid hormones, e.g. T3, T4
    • A61P5/16—Drugs for disorders of the endocrine system of the thyroid hormones, e.g. T3, T4 for decreasing, blocking or antagonising the activity of the thyroid hormones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/38—Drugs for disorders of the endocrine system of the suprarenal hormones
    • A61P5/46—Drugs for disorders of the endocrine system of the suprarenal hormones for decreasing, blocking or antagonising the activity of glucocorticosteroids
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C217/00—Compounds containing amino and etherified hydroxy groups bound to the same carbon skeleton
    • C07C217/78—Compounds containing amino and etherified hydroxy groups bound to the same carbon skeleton having amino groups and etherified hydroxy groups bound to carbon atoms of six-membered aromatic rings of the same carbon skeleton
    • C07C217/80—Compounds containing amino and etherified hydroxy groups bound to the same carbon skeleton having amino groups and etherified hydroxy groups bound to carbon atoms of six-membered aromatic rings of the same carbon skeleton having amino groups and etherified hydroxy groups bound to carbon atoms of non-condensed six-membered aromatic rings
    • C07C217/82—Compounds containing amino and etherified hydroxy groups bound to the same carbon skeleton having amino groups and etherified hydroxy groups bound to carbon atoms of six-membered aromatic rings of the same carbon skeleton having amino groups and etherified hydroxy groups bound to carbon atoms of non-condensed six-membered aromatic rings of the same non-condensed six-membered aromatic ring
    • C07C217/90—Compounds containing amino and etherified hydroxy groups bound to the same carbon skeleton having amino groups and etherified hydroxy groups bound to carbon atoms of six-membered aromatic rings of the same carbon skeleton having amino groups and etherified hydroxy groups bound to carbon atoms of non-condensed six-membered aromatic rings of the same non-condensed six-membered aromatic ring the oxygen atom of at least one of the etherified hydroxy groups being further bound to a carbon atom of a six-membered aromatic ring, e.g. amino-diphenylethers
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C233/00—Carboxylic acid amides
    • C07C233/01—Carboxylic acid amides having carbon atoms of carboxamide groups bound to hydrogen atoms or to acyclic carbon atoms
    • C07C233/56—Carboxylic acid amides having carbon atoms of carboxamide groups bound to hydrogen atoms or to acyclic carbon atoms having carbon atoms of carboxamide groups bound to carbon atoms of carboxyl groups, e.g. oxamides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C235/00—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by oxygen atoms
    • C07C235/02—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by oxygen atoms having carbon atoms of carboxamide groups bound to acyclic carbon atoms and singly-bound oxygen atoms bound to the same carbon skeleton
    • C07C235/32—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by oxygen atoms having carbon atoms of carboxamide groups bound to acyclic carbon atoms and singly-bound oxygen atoms bound to the same carbon skeleton the carbon skeleton containing six-membered aromatic rings
    • C07C235/34—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by oxygen atoms having carbon atoms of carboxamide groups bound to acyclic carbon atoms and singly-bound oxygen atoms bound to the same carbon skeleton the carbon skeleton containing six-membered aromatic rings having the nitrogen atoms of the carboxamide groups bound to hydrogen atoms or to acyclic carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C59/00—Compounds having carboxyl groups bound to acyclic carbon atoms and containing any of the groups OH, O—metal, —CHO, keto, ether, groups, groups, or groups
    • C07C59/40—Unsaturated compounds
    • C07C59/58—Unsaturated compounds containing ether groups, groups, groups, or groups
    • C07C59/64—Unsaturated compounds containing ether groups, groups, groups, or groups containing six-membered aromatic rings
    • C07C59/66—Unsaturated compounds containing ether groups, groups, groups, or groups containing six-membered aromatic rings the non-carboxylic part of the ether containing six-membered aromatic rings
    • C07C59/68—Unsaturated compounds containing ether groups, groups, groups, or groups containing six-membered aromatic rings the non-carboxylic part of the ether containing six-membered aromatic rings the oxygen atom of the ether group being bound to a non-condensed six-membered aromatic ring
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C59/00—Compounds having carboxyl groups bound to acyclic carbon atoms and containing any of the groups OH, O—metal, —CHO, keto, ether, groups, groups, or groups
    • C07C59/40—Unsaturated compounds
    • C07C59/76—Unsaturated compounds containing keto groups
    • C07C59/90—Unsaturated compounds containing keto groups containing singly bound oxygen-containing groups
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C65/00—Compounds having carboxyl groups bound to carbon atoms of six—membered aromatic rings and containing any of the groups OH, O—metal, —CHO, keto, ether, groups, groups, or groups
    • C07C65/32—Compounds having carboxyl groups bound to carbon atoms of six—membered aromatic rings and containing any of the groups OH, O—metal, —CHO, keto, ether, groups, groups, or groups containing keto groups
    • C07C65/40—Compounds having carboxyl groups bound to carbon atoms of six—membered aromatic rings and containing any of the groups OH, O—metal, —CHO, keto, ether, groups, groups, or groups containing keto groups containing singly bound oxygen-containing groups
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C69/00—Esters of carboxylic acids; Esters of carbonic or haloformic acids
    • C07C69/66—Esters of carboxylic acids having esterified carboxylic groups bound to acyclic carbon atoms and having any of the groups OH, O—metal, —CHO, keto, ether, acyloxy, groups, groups, or in the acid moiety
    • C07C69/73—Esters of carboxylic acids having esterified carboxylic groups bound to acyclic carbon atoms and having any of the groups OH, O—metal, —CHO, keto, ether, acyloxy, groups, groups, or in the acid moiety of unsaturated acids
    • C07C69/734—Ethers
    • C07C69/736—Ethers the hydroxy group of the ester being etherified with a hydroxy compound having the hydroxy group bound to a carbon atom of a six-membered aromatic ring
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C69/00—Esters of carboxylic acids; Esters of carbonic or haloformic acids
    • C07C69/76—Esters of carboxylic acids having a carboxyl group bound to a carbon atom of a six-membered aromatic ring
    • C07C69/84—Esters of carboxylic acids having a carboxyl group bound to a carbon atom of a six-membered aromatic ring of monocyclic hydroxy carboxylic acids, the hydroxy groups and the carboxyl groups of which are bound to carbon atoms of a six-membered aromatic ring
    • C07C69/92—Esters of carboxylic acids having a carboxyl group bound to a carbon atom of a six-membered aromatic ring of monocyclic hydroxy carboxylic acids, the hydroxy groups and the carboxyl groups of which are bound to carbon atoms of a six-membered aromatic ring with etherified hydroxyl groups

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Diabetes (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Veterinary Medicine (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Endocrinology (AREA)
  • Ophthalmology & Optometry (AREA)
  • Child & Adolescent Psychology (AREA)
  • Dermatology (AREA)
  • Emergency Medicine (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Steroid Compounds (AREA)
  • Pyrrole Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
SE99936913T 1998-08-05 1999-08-04 SE1102739T5 (cg-RX-API-DMAC10.html)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
GBGB9816935.2A GB9816935D0 (en) 1998-08-05 1998-08-05 Novel glucocortoid and thyroid receptor ligands for the treatment of metabolic disorders

Publications (2)

Publication Number Publication Date
SE1102739T3 SE1102739T3 (cg-RX-API-DMAC10.html) 2003-08-12
SE1102739T5 true SE1102739T5 (cg-RX-API-DMAC10.html) 2003-09-16

Family

ID=10836671

Family Applications (1)

Application Number Title Priority Date Filing Date
SE99936913T SE1102739T5 (cg-RX-API-DMAC10.html) 1998-08-05 1999-08-04

Country Status (26)

Country Link
US (1) US6492424B1 (cg-RX-API-DMAC10.html)
EP (1) EP1102739B1 (cg-RX-API-DMAC10.html)
JP (1) JP2002522407A (cg-RX-API-DMAC10.html)
KR (1) KR20010072113A (cg-RX-API-DMAC10.html)
CN (1) CN1311767A (cg-RX-API-DMAC10.html)
AT (1) ATE238267T1 (cg-RX-API-DMAC10.html)
AU (1) AU753376B2 (cg-RX-API-DMAC10.html)
BG (1) BG105214A (cg-RX-API-DMAC10.html)
BR (1) BR9912742A (cg-RX-API-DMAC10.html)
CA (1) CA2339194A1 (cg-RX-API-DMAC10.html)
DE (1) DE69907210T2 (cg-RX-API-DMAC10.html)
DK (1) DK1102739T3 (cg-RX-API-DMAC10.html)
ES (1) ES2193730T3 (cg-RX-API-DMAC10.html)
GB (1) GB9816935D0 (cg-RX-API-DMAC10.html)
HU (1) HUP0103222A3 (cg-RX-API-DMAC10.html)
ID (1) ID28805A (cg-RX-API-DMAC10.html)
IL (1) IL141106A0 (cg-RX-API-DMAC10.html)
MX (1) MXPA01001047A (cg-RX-API-DMAC10.html)
NO (1) NO20010610L (cg-RX-API-DMAC10.html)
PL (1) PL345824A1 (cg-RX-API-DMAC10.html)
SE (1) SE1102739T5 (cg-RX-API-DMAC10.html)
SI (1) SI20579A (cg-RX-API-DMAC10.html)
SK (1) SK942001A3 (cg-RX-API-DMAC10.html)
TR (1) TR200100274T2 (cg-RX-API-DMAC10.html)
WO (1) WO2000007972A1 (cg-RX-API-DMAC10.html)
ZA (1) ZA200100832B (cg-RX-API-DMAC10.html)

Families Citing this family (31)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2000051971A1 (en) 1999-03-01 2000-09-08 Pfizer Products Inc. Oxamic acids and derivatives as thyroid receptor ligands
US6790978B2 (en) 1999-03-29 2004-09-14 Novartis Ag Thyromimetic organic compounds
US6599942B1 (en) 1999-03-29 2003-07-29 Novartis Ag Thyromimetic organic compounds
GB9928805D0 (en) * 1999-12-07 2000-02-02 Karobio Ab Compounds active at the Glucocorticoid and Thyroid Hormone Receptors
US6664291B2 (en) 2000-03-31 2003-12-16 Pfizer, Inc. Malonamic acids and derivatives thereof as thyroid receptor ligands
DE10038007A1 (de) * 2000-08-04 2002-02-14 Bayer Ag Neue Amino-und Amido-Diphenylether für Arzneimittel
ES2246292T3 (es) 2000-10-30 2006-02-16 Pfizer Products Inc. Moduladores de receptor glucocorticoide.
AU2001216038A1 (en) * 2000-11-14 2002-05-27 Alcon Laboratories Inc. Treatment of glaucoma and ocular hypertension
GB0029102D0 (en) 2000-11-29 2001-01-10 Karobio Ab Compounds active at the glucocorticoid receptor
GB0029100D0 (en) * 2000-11-29 2001-01-10 Karobio Ab Compounds active at the glucocorticoid receptor
US6583180B2 (en) 2001-02-14 2003-06-24 Abbott Laboratories Glucocorticoid receptor modulators
US6777442B2 (en) * 2001-03-12 2004-08-17 Bayer Aktiengesellschaft Diphenyl derivatives
GB0111861D0 (en) 2001-05-15 2001-07-04 Karobio Ab Novel compounds
KR20040027927A (ko) 2001-08-24 2004-04-01 카로 바이오 아베 심장 및 대사 장애의 치료를 위해 주요 환이 치환된갑상선 수용체 길항근
GB0120691D0 (en) * 2001-08-24 2001-10-17 Karobio Ab Novel Compounds
DE60208132T2 (de) 2001-09-26 2006-07-20 Pfizer Products Inc., Groton Indolcaroboxylsäure als Thyroidrezeptor-Liganden
WO2003026632A2 (en) 2001-09-26 2003-04-03 Theravance, Inc. Substituted phenol compounds useful for anesthesia and sedation
CA2473886C (en) 2002-01-22 2012-08-21 The Regents Of The University Of California Non-steroidal ligands for the glucocorticoid receptor, compositions and uses thereof
CA2473162A1 (en) 2002-01-30 2003-08-07 Kissei Pharmaceutical Co., Ltd. Novel thyroid hormone receptor ligand, medicinal compositions containing the same and use thereof
GB0215978D0 (en) * 2002-07-10 2002-08-21 Karobio Ab Novel compounds
AU2002951977A0 (en) 2002-10-10 2002-10-24 Leo Engineering Pty Ltd Improvements to two-part vessels
EP2428516A1 (en) * 2003-11-19 2012-03-14 Metabasis Therapeutics, Inc. Novel phosphorus-containing thyromimetics
GB0406378D0 (en) * 2004-03-22 2004-04-21 Karobio Ab Novel pharmaceutical compositions
US20090232879A1 (en) * 2005-05-26 2009-09-17 Metabasis Therapeutics, Inc. Thyromimetics for the Treatment of Fatty Liver Diseases
RU2007148927A (ru) * 2005-05-26 2009-07-10 Метабэйзис Терапьютикс, Инк. (Us) Новые тиреомиметики, содержащие фосфиновую кислоту
WO2009129225A1 (en) * 2008-04-15 2009-10-22 Osteogenex, Inc. Compounds and methods for altering bone growth
WO2018094265A2 (en) 2016-11-21 2018-05-24 Viking Therapeutics, Inc. Method of treating glycogen storage disease
AU2018280118B2 (en) 2017-06-05 2021-07-15 Viking Therapeutics, Inc. Compositions for the treatment of fibrosis
EA202091979A1 (ru) 2018-03-22 2021-06-22 Вайкинг Терапьютикс, Инк. Кристаллические формы и способы получения кристаллических форм соединения
EP4775207A2 (en) 2018-12-05 2026-07-15 Viking Therapeutics, Inc. Compositions for the treatment of fibrosis
EP4161925A4 (en) 2020-06-09 2024-09-04 Viking Therapeutics, Inc. COMPOSITIONS AND METHODS FOR THE TREATMENT OF LIVER DISEASES

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0580550B1 (en) * 1992-07-21 1997-10-22 Novartis AG Oxamic acid derivatives as hypocholesteremic agents
WO1999063976A2 (en) * 1998-06-08 1999-12-16 Karo Bio Ab Liver-selective glucocorticoid antagonist for treating diabetes

Also Published As

Publication number Publication date
WO2000007972A1 (en) 2000-02-17
SK942001A3 (en) 2001-12-03
AU753376B2 (en) 2002-10-17
ZA200100832B (en) 2001-10-31
KR20010072113A (ko) 2001-07-31
HUP0103222A3 (en) 2002-12-28
NO20010610D0 (no) 2001-02-05
EP1102739A1 (en) 2001-05-30
DE69907210T2 (de) 2004-02-19
BR9912742A (pt) 2001-05-02
AU5188199A (en) 2000-02-28
JP2002522407A (ja) 2002-07-23
CN1311767A (zh) 2001-09-05
ID28805A (id) 2001-07-05
IL141106A0 (en) 2002-02-10
ES2193730T3 (es) 2003-11-01
TR200100274T2 (tr) 2001-09-21
ATE238267T1 (de) 2003-05-15
EP1102739B1 (en) 2003-04-23
US6492424B1 (en) 2002-12-10
SE1102739T3 (cg-RX-API-DMAC10.html) 2003-08-12
HUP0103222A2 (hu) 2002-01-28
GB9816935D0 (en) 1998-09-30
CA2339194A1 (en) 2000-02-17
DE69907210D1 (de) 2003-05-28
PL345824A1 (en) 2002-01-14
MXPA01001047A (es) 2002-09-02
NO20010610L (no) 2001-04-04
SI20579A (sl) 2001-12-31
DK1102739T3 (da) 2003-08-18
BG105214A (en) 2001-12-29

Similar Documents

Publication Publication Date Title
SE1102739T3 (cg-RX-API-DMAC10.html)
CA2294098A1 (en) Novel thyroid receptor ligands and method
NZ512422A (en) Novel thyroid receptor ligands and method II
CZ85395A3 (en) Derivatives of vaprooic and 1-valproenic acids and pharmaceutical preparations based thereon
IL126339A (en) Taxol derivatives
ATE215078T1 (de) Verbessertes verfahren zum herstellen von geschützten 3,4-dihydroxybuttersäure estern
CA2234567A1 (en) Azaindole-ethylamine derivatives as nicotinic acetylcholine receptor binding agents
RU93005332A (ru) Производные 4,1-бензоксазепина, фармацевтическая композиция, способ лечения
AU2251901A (en) Methods and compounds for inhibiting MRP1
Stoeckel et al. Stability of cephalosporin prodrug esters in human intestinal juice: implications for oral bioavailability
CA2053820A1 (en) Method of Inhibiting Metabolism of Cholesterol
BG102350A (en) New derivatives of 5-0-desozaminyl-6-0-methylerythronolide a, method for their preparation and usage for the preparation of biologically active products
PL312788A1 (en) Benzopyranes and pharmaceutical compounds containing them
WO2001051004A3 (en) Anti-cancer agent containing naphthoquinone compound
PL312212A1 (en) Method of obtaining oxazolydinocarboxylic acid suitable for use in production of taxoides exhibiting therapeutic properties
EP0666263A4 (cg-RX-API-DMAC10.html)
AU6092396A (en) Ether derivatives of pseudopterosin
JPS5524127A (en) 3,6-endomethylene-delta4-1,2,3,6-tetrahydrophtalimide derivative
JPS56120686A (en) Tetrahydrothiopyrano 3,2-b indole derivative
TW290536B (en) The derivatives and the prepared method of 2,2-dimethyl-5-substituted phenoxy-pentanoic acids
JPS6481A (en) H2-receptor antagonist compound